Single infusion of neridronate (6-amino-1-hydroxy-hexylidene-1, 1-bisphosphonate) in patients with active rheumatoid arthritis: Effects on disease activity and bone resorption markers

Aging Clinical and Experimental Research

Volumn 14, Issue 3, 2002, Pages 197-201

  Mazzantini, Maurizio ^a   Di Munno, Ombretta ^a   Metelli, Maria Rita ^a   Bulleri, Marco ^a   Giordani, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Bisphosphonates; Bone resorption markers; Neridronate; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INFUSION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; MALE; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; URINALYSIS;

AGED; AMINO ACIDS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BONE RESORPTION; C-REACTIVE PROTEIN; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYPROLINE; MALE; MIDDLE AGED; PEPTIDES;

EID: 0036623621     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324436     Document Type: Article

References (28)

1. Francis MD, Flora L, King WR. The effects of disodium ethane-1-hydroxy-1, 1-diphosphonate on adjuvant induced arthritis in rats. Calcif Tissue Int 1972; 9: 109-21.
2. Flora L. Comparative antinflammatory and bone protective effects of two disphosphonates in adjuvant arthritis. Arthritis Rheum 1979; 22: 340-6.
3. Kong AS, Shas J, Rappo R, Leibowitz M. Effects of disphosphonates on rat adjuvant arthritis. Int J Immunopharmacol 1982; 4: 311.
4. Glatt M, Blätter A, Bisping M, Bray MA. Effects of diphosphonates (APD, EHDP) on inflammation and bone turnover in adjuvant arthritis rats. Experientia 1983; 39: 681.
5. Barbier A, Breliere JC, Remandet B, Roncucci R. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986; 45: 67-74.
6. Kinne RW, Schmidt-Weber CB, Hoppe R, et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995; 38: 1777-90.
7. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 1995; 44: 258-63.
8. Osterman T, Virtamo T, Lauren L, et al. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J Pharmacol Exp Ther 1997; 280: 1001-7.
9. Richards PJ, Williams AS, Goodfellow RM, Williams BD. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology 1999; 38: 818-25.
10. de Vries E, van der Weij JP, van der Veen CJ, et al. In vitro effect of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 1982; 47: 157-63.
11. Felix R, Bettex JD, Fleish H. The effects of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 1981; 33: 549-52.
12. Ohya K, Yamada S, Felix R, Heish H. Effects of bisphosphonates on prostaglandin synthesis by rat bone cells and mouse calvaria. in culture. Clin Sci 1985; 69: 403-11.
13. Konttinen YT, Salo T, Hanemaaijer R. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999; 18: 401-12.
14. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998; 27: 38-41.
15. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318-23.
16. Eggelmeiijer F, Papapoulos SE, Van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind, placebo controlled study. J Rheumatol 1994; 21: 2016-20.
17. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russel AS. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998; 25: 714-7.
18. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 396-9.
19. Richards PJ, Amos N, Williams AS, Williams BD. Pro-inflammatory effects of ibandronate in vitro and in vivo. Rheumatology 1999; 38: 984-91.
20. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996; 119: 205-12.
21. Makkonen M, Salminen A, Rogers MJ. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 1999; 8: 109-18.
22. Delmas PD, Chapuy MC, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987; 83: 276-82.
23. Filipponi P, Cristallini S, Policani G, Casciari C, Gregorio, F. Paget's disease of bone: benefits of neridronate as a first treatment and in case of relapse after clodronate. Bone 1998; 23: 543-8.
24. O'Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994; 69: 914-7.
25. Tobias JH, Laversuch CV, Wilson N, Robins SP. Neridronate preferentially suppresses the urinary excretion of peptide-bound deoxypyridinoline in postmenopausal women. Calcif Tissue Int 1996; 59: 407-9.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. Deodhar AA, Woolf AD. Bone mass measurements and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 309-22.
28. Garnero P, Delmas PD. Biochemical markers of bone turnover. Application for osteoporosis. Endocrinol Metab Clin North Am 1998; 27: 303-23.